01:54

Closing Remarks

39:00

The Future of ART

43:45

Updates in STI Prevention and Treatment: DoxyPEP and More

44:36

“Weighing In” on GLP-1 Receptor Agonists for People With HIV

47:12

Preventing Heart Disease in People with HIV: Delivering REPRIEVE from a Major Comorbidity

46:10

Sex, Drugs, and ART: Addressing Substance Use in People with HIV

08:24

Welcome and Introduction

44:36

“Weighing In” on GLP-1 Receptor Agonists for People With HIV

43:45

Updates in STI Prevention and Treatment: DoxyPEP and More

39:00

The Future of ART

01:54

Closing Remarks

08:24

Welcome and Introductions

46:10

Sex, Drugs, and ART: Addressing Substance Use in People with HIV

47:12

Preventing Heart Disease in People with HIV: Delivering REPRIEVE from a Major Comorbidity

01:14:23

Addressing the Humdrum and Conundrum: A PEP and PrEP Case Discussion

43:41

Future Directions of Investigational Antiretroviral Therapy

45:15

Beyond Viral Suppression: How Addressing Mental Health Reduces Morbidity&Mortality in People w/ HIV

44:48

Routine and Special Immunizations in HIV: 2023 Update

04:11

Day 3 Welcome and Introduction

43:19

Diagnosis, Prevention, and Management of Syphilis: A Lata Good Information

45:41

Beyond the X-Waiver: How HIV Practitioners Can Help End the Opioid Crisis

39:01

Drug-Drug Interactions: Illicit Drug Interactions With HAART

49:24

Beating Burnout: Building a Culture of Resilience and Wellness

43:57

HIV Vaccines and Monoclonal Antibodies – What’s Taking So Long and Why

05:01

Day 2 Welcome

42:26

Doxycycline for STI Prevention: Evidence and Implementation

46:59

HIV and Pregnancy: Current Consensus and Controversies

47:34

Results From the REPRIEVE Trial: Implications for the Clinical Care of Patients with HIV

48:28

Addressing Challenges in Alzheimer’s Disease in People with HIV

18:43

Day 1 Welcome and Introduction

39:11

HIV and Inflamm-Aging: How Do We Reach the Summit of Healthy Aging?

34:42

No Mo FOMO: In Case You Missed It; Changes in Guidelines, Publications, & Updates from Conferences

41:13

HRSA Ryan White HIV/AIDS Program Updates

01:19:00

(Part 4 of 6) Substance Use Disorder: Alcohol and Tobacco Use Disorders in Patients With HIV

41:04

Resistance in Long-Acting Therapy for Prevention and Treatment: Uncommon Outcome or Achilles Heel

01:30:50

HIV 101: Initial Assessment, Initiation of ART, and Monitoring of People With Newly Diagnosed HIV

07:47

Welcome and Introductions

43:52

State of the Science: What We Know about Long-Acting Injectable Agents for Treatment of HIV

41:25

State of the Science: What We Know about Long-Acting Injectable Agents for HIV Prevention

56:07

Navigating the Operational Challenges of Long-Acting Treatment and Prevention Strategies

01:12:24

Challenging Cases in Long-Acting Treatment and Prevention: What Would You Do?

02:41

Closing Remarks

01:14:25

Respiratory Syncytial Virus and Influenza Infections: New Immunization Approaches for Children

01:16:51

Cardiovascular Disease Prevention in Patients With HIV: The REPRIEVE Trial

01:01:29

(October 19, 2023) Latest Update on Urgent Virus Outbreaks: October 2023

01:20:54

(Part 3 of 6) SUD: Initiating Buprenorphine in the Fentanyl Era and Other Treatment Considerations

01:18:23

Doxy-PEP: Who, When, and How?

01:27:02

(Part 2 of 6) Substance Use Disorder (SUD) 101: How Should We Care For SUD in Patients With HIV?

01:34:59

What to Do Next: Use of Resistance Testing and Managing ART Failure in People With HIV

01:17:57

Overview of Data Presented at the 2023 International AIDS Conference

01:14:19

(Part 1 of 6) Substance Use Disorder (SUD) 101: Why Should We Care About SUD in Patients With HIV?

01:23:34

Routine and Special Immunizations for People With HIV

01:00:16

(August 1, 2023) Latest Update on Urgent Virus Outbreaks August 2023

01:46:37

Basics of HIV Drug Resistance Mutation

02:44

Closing Remarks

06:21

Welcome and Introductions

33:03

Long COVID and HIV

36:09

Patient Perspective: Long COVID

33:46

Long COVID Clinical Trials

01:11:36

Evaluation and Management of Long COVID: A Case-Based Panel Discussion